Johnson & Johnson Acquires Laminary in $400 Million Deal

by webmaster

Johnson & Johnson, a leading medical device company, has recently announced its acquisition of Laminary. The privately held medical device company was acquired for an upfront payment of $400 million.

Willing to try automated trading?
See the best forex robots rating to make the right choice.
Explore the list here >

Revised Full-Year Profit Outlook

In light of this deal, Johnson & Johnson has revised its full-year adjusted profit outlook. The company now expects a reduction in earnings next year by approximately 15 cents per share. Consequently, the target for adjusted earnings in 2023 has been adjusted to $9.90 to $9.96 per share, with operational adjusted earnings projected at $9.85 to $9.91 per share.

The revision in earnings is due to an in-process research-and-development charge associated with the acquisition.

Laminary’s Focus and Implications

Laminary specializes in the treatment of non-valvular atrial fibrillation (AFib) by eliminating the left atrial appendage. With around 38 million individuals worldwide suffering from AFib, the acquisition of Laminary by Johnson & Johnson holds significant implications. AFib patients are five times more likely to experience a stroke, making this a crucial area of focus for J&J.

Integration with J&J MedTech

Laminary will become part of the Biosense Webster business under J&J MedTech’s umbrella. The Biosense Webster business primarily focuses on cardiac arrhythmia treatments. In addition to the upfront payment of $400 million, there may also be additional clinical and regulatory milestone payments associated with the acquisition.

Willing to try automated trading?
See the best forex robots rating to make the right choice.
Explore the list here >

Related Articles

Leave a Comment

60 + = 62